The 2018 Agriculture Improvement Act (the Farm Bill) removed hemp—defined as Cannabis sativa L. and its derivatives containing not more than 0.3% Delta-9 THC on a dry-weight basis—from the federal Controlled Substances Act [1]. The Farm Bill did not, however, change FDA's authority over products marketed for human or animal consumption [2]. Under the Federal Food, Drug, and Cosmetic Act, FDA has taken the following positions:

• CBD and THC are not approved by FDA as food additives, and FDA has stated it cannot conclude that CBD is Generally Recognized as Safe (GRAS) for use in human or animal food [2, 3].
• CBD and THC are excluded from the statutory definition of a dietary supplement under section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act [4]. This product is not, and is not marketed as, a dietary supplement.
• FDA has approved only one prescription drug containing CBD (Epidiolex) for specific seizure disorders [2, 5]. No other CBD or THC product has been evaluated or approved by FDA for the diagnosis, treatment, cure, mitigation, or prevention of any disease.
• This product is intended for adult recreational use only. It is not a medicine, supplement, or therapeutic product.

Sources for this section: [1] 2018 Farm Bill (Pub. L. 115-334). [2] FDA Consumer Update on CBD. [3] FDA Scientific Memorandum on CBD (2022). [4] 21 U.S.C. § 321(ff)(3)(B). [5] EPIDIOLEX Prescribing Information.

The statement above is taken verbatim from FDA's consumer update titled "What You Need to Know (And What We're Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD" [2]. FDA's concern over CBD-related liver effects was first identified during the clinical trials supporting Epidiolex, where dose-related transaminase elevations were observed and led to labeled monitoring requirements [5]. A 2025 FDA-led randomized, double-blind, placebo-controlled clinical trial in healthy adults (Florian et al., JAMA Internal Medicine, July 2025) reported that 5.6% of participants taking oral CBD at 5 mg/kg per day (approximately 250–550 mg/day depending on body weight) for 28 days developed elevations in the liver enzymes ALT or AST greater than three times the upper limit of normal. Of the eight participants who experienced elevations, five were female. Enzyme elevations resolved within one to two weeks after CBD was discontinued [6, 7].

General clinical guidance (not FDA-issued):Drug-induced liver injury can develop without obvious symptoms in its early stages [8]. Clinicians commenting on the 2025 study have suggested that consumers using CBD regularly may benefit from periodic liver function testing, particularly those with a history of liver disease, those taking medications metabolized by the liver, or those who consume alcohol. Stop use and consult a healthcare provider if you experience yellowing of the skin or eyes, dark urine, persistent nausea, abdominal pain (especially upper-right), unusual fatigue, or loss of appetite [8].

Sources for this section: [1] 2018 Farm Bill (Pub. L. 115-334). [2] FDA Consumer Update on CBD. [3] FDA Scientific Memorandum on CBD (2022). [4] 21 U.S.C. § 321(ff)(3)(B). [5] EPIDIOLEX Prescribing Information.

CBD and THC affect how the body metabolizes other medications by inhibiting key liver enzymes, including the cytochrome P450 family (particularly CYP3A4, CYP2C9, and CYP2C19) and several UGT enzymes [5, 9]. This can increase or decrease blood levels of other drugs, leading to either reduced effectiveness or increased toxicity. Talk to your physician or pharmacist before using this product if you take any of the following:

• Blood thinners or anticoagulants, particularly warfarin. A 2023 systematic review identified seven case reports of warfarin–cannabinoid interactions, with elevated INR documented in six of seven cases (range +0.4 to +9.61), attributed to CYP2C9 inhibition by CBD and THC [10, 11].
• Antiepileptic and seizure medications. The Epidiolex prescribing information specifically identifies clobazam (CBD coadministration increases the active metabolite N-desmethylclobazam approximately threefold) and valproate (combined use increases the incidence of liver enzyme elevations) [5].
• Antidepressants, antipsychotics, and benzodiazepines, many of which are metabolized by CYP3A4, CYP2D6, or CYP2C19—enzymes that CBD inhibits in vitro at clinically relevant concentrations [5, 9].
• Opioid pain medications, many of which are CYP3A4 substrates [9].
• Immunosuppressants. The Epidiolex label specifically calls out everolimus (CBD increases its exposure) and recommends a lower starting dose with appropriate therapeutic drug monitoring [5].
• Other medications metabolized by CYP3A4, CYP2C9, CYP2C19, CYP2D6, CYP1A2, or UGT enzymes—a list that includes some statins, beta-blockers, antihistamines, antifungals, and antibiotics [9]. The clinical significance of many of these interactions has not been fully characterized.
• Any other prescription, over-the-counter medication, herb, or dietary supplement. FDA specifically advises caution when combining CBD products with herbs or dietary supplements [2].

Sources for this section: [2] FDA Consumer Update on CBD. [5] EPIDIOLEX Prescribing Information § 7 and § 12.3. [9] Brown & Winterstein, J Clin Med (2019); Doohan et al., AAPS J (2021). [10] Smythe et al., Pharmacotherapy 2023. [11] Grayson et al., Epilepsy Behav Case Rep 2018.

The statement above is FDA guidance on CBD specifically [2]. Because this product also contains Delta-9 THC and CBN, the same caution applies. THC and CBN have well-documented sedative and impairing properties of their own; federal Drug Recognition Expert protocols place cannabis in its own pharmacological category rather than classifying it strictly as a CNS depressant [12]. Combining this product with alcohol, sleep medications, opioids, benzodiazepines, or other sedating substances may produce additive effects, including pronounced drowsiness, slowed reaction time, impaired coordination, and impaired judgment [5]. The packaging directs you not to drive or operate machinery; that warning is amplified when this product is combined with other depressants.

Sources for this section: [2] FDA Consumer Update on CBD. [5] EPIDIOLEX Prescribing Information. [12] IACP, "7 Drug Categories" (DRE classification).

FDA has reported that studies in laboratory animals showed CBD-related male reproductive toxicity, including in the male offspring of CBD-treated pregnant females [2]. The specific changes reported by FDA include:

• Decrease in testicular size [2].
• Inhibition of sperm growth and development [2].
• Decreased circulating testosterone [2].

These findings have been observed in animal studies (including rhesus monkeys and rodents) and the implications for human fertility are not yet fully understood [2, 13]. FDA has stated that further research is needed and has specifically listed "Does CBD cause male reproductive toxicity in humans, as has been reported in studies of animals?" as an open question [2]. Consumers who are trying to conceive, or who have concerns about fertility, should discuss CBD/THC use with their physician.

Sources for this section: [2] FDA Consumer Update on CBD (verbatim language). [13] Carvalho et al., J Appl Toxicol 2020.

The statement above is taken verbatim from FDA's consumer update on cannabis use during pregnancy and breastfeeding [14]. FDA further states that high doses of CBD in pregnant test animals have caused problems with the reproductive system of developing male fetuses, and that, based on what is known about CBD, FDA expects that some amount of CBD will be transferred to babies through breast milk [14]. The U.S. Surgeon General has separately advised that THC can enter the fetal brain through a mother's bloodstream and may increase the risk of low birth weight [15]. THC may remain detectable in breast milk for up to six days after use [14].

If you become pregnant while using this product, discontinue use immediately and consult your healthcare provider. The packaging instructs anyone who is pregnant, breastfeeding, or taking any medication to consult their physician before use.

Sources for this section: [14] FDA Consumer Update on cannabis use during pregnancy and breastfeeding. [15] U.S. Surgeon General's Advisory: Marijuana Use and the Developing Brain (2019).

FDA has identified the following categories of side effects that may occur with CBD use [2]. These side effects are generally expected to improve when CBD is stopped or when the amount used is reduced. Because this product also contains Delta-9 THC and CBN, additional psychoactive and sedative effects are expected [16].

Changes in Alertness (FDA-stated [2])

• Most commonly reported as somnolence (drowsiness, sleepiness).
• Can also include insomnia, restlessness, or disturbed sleep.
• Slowed reaction time, reduced coordination, and impaired judgment.

Gastrointestinal Distress (FDA-stated [2])

• Diarrhea.
• Decreased appetite.
• Abdominal pain or upset stomach.
• Nausea or vomiting.

Changes in Mood (FDA-stated [2])

• Irritability and agitation.
• Anxiety, paranoia, or panic—particularly with higher THC doses [16, 17].
• Confusion or disorientation.

Other Commonly Reported Effects (peer-reviewed cannabis pharmacology literature, not FDA-stated)

• Dry mouth and dry eyes [16].
• Reddened eyes / conjunctival injection [16].
• Increased heart rate (tachycardia), particularly within the first 1–2 hours of use [16].
• Transient drops in blood pressure that can cause dizziness on standing [16].
• Headache [16].
• Tremor or shakiness, more commonly reported with overconsumption [17].
• In rare cases, hallucinations or loss of consciousness, particularly with overconsumption. FDA has specifically reported these among adverse events involving Delta-8 THC products [18].

Discontinue use and seek medical attention if you experience symptoms that are severe, do not resolve, or are otherwise concerning.

Sources for this section: [2] FDA Consumer Update on CBD. [16] National Academies (2017), "Health Effects of Cannabis and Cannabinoids." [17] NIDA Research Report on Cannabis. [18] FDA, "5 Things to Know About Delta-8 THC."

FDA and CDC have warned of an increase in adverse-event reports involving THC-containing edible products [18, 19]. Because edibles can take up to two hours to take effect [16, 20], consumers may inadvertently consume additional servings before the first serving has set in. Adverse effects associated with THC overconsumption include:

• Severe anxiety, panic, or paranoia [16, 17].
• Hallucinations or altered perception [18].
• Vomiting (including, in rare cases of chronic heavy use, cannabinoid hyperemesis syndrome) [21].
• Tremor and muscle weakness [17].
• Dizziness, confusion, and disorientation [16].
• Significantly elevated or, less commonly, depressed heart rate [16].
• Loss of consciousness in extreme cases [18].
• Acute psychiatric symptoms, particularly in individuals with a personal or family history of psychotic disorders [22].

Sources for this section: [16] National Academies (2017). [17] NIDA Research Report. [18] FDA Delta-8 Update. [19] CDC HAN-00451 (2021). [20] Barrus et al., RTI Press 2016. [21] Allen et al., Gut 2004 / Cleveland Clinic. [22] Manseau & Goff, Neurotherapeutics 2015.

Cannabis edibles—particularly gummies, chocolates, candies, and cookies—are a leading source of accidental exposure in children and pets because they can be visually mistaken for ordinary candy [19, 23]. The American Association of Poison Control Centers, the CDC's Health Alert Network, and FDA have all issued public-health communications on this issue [18, 19, 23]. A 2023 retrospective analysis of National Poison Data System data published in Pediatrics documented a 1,375% increase in pediatric edible cannabis exposures in children under age six between 2017 and 2021, with 22.7% of all reported cases admitted to the hospital and central nervous system depression reported in 70% of followed cases [23]. Reported pediatric outcomes have ranged from drowsiness and vomiting to deep sedation, respiratory depression, oxygen support, intubation, and intensive care admission [19, 23].

To prevent accidental exposure:

• Always store this product in its original child-resistant packaging.
• Keep the product out of sight and out of reach of children, including in a locked cabinet or container if children may be present [19].
• Do not consume this product in the presence of children or pets.
• Never refer to cannabis edibles as candy in front of children.
• Pets, especially dogs, are highly sensitive to THC due to a higher density of cannabinoid (CB1) receptors in their brains compared to humans [24]. Even a small amount can cause severe toxicity [24]. Keep this product entirely out of reach of pets.
• If a child or pet ingests this product, contact Poison Control or a veterinarian immediately—do not wait for symptoms to appear.

Sources for this section: [18] FDA Delta-8 Update. [19] CDC HAN-00451 (Sept 2021). [23] Tweet, Nemanich & Wahl, Pediatrics 2023;151(2). [24] Cornell University College of Veterinary Medicine

Although this product is formulated with fast-acting nano technology designed to begin onset as soon as 15 minutes (per manufacturer formulation), the full effects of an edible cannabinoid product may be delayed up to 2 hours and may persist for 4–8 hours or longer [20]. Peak effects of oral THC typically occur approximately 3 hours after ingestion based on peer-reviewed pharmacokinetic data [20]. Individual response varies based on:

• Body weight and body composition [20].
• Metabolism and liver enzyme activity [20].
• Whether the product is taken with food, and the type and quantity of food consumed [20].
• Tolerance from prior cannabis use [16].
• Age, sex, hormonal status, and genetics [16].
• Concurrent use of other medications, supplements, alcohol, or substances [9].
• Hydration, sleep, and overall health status.

First-time users and those with low tolerance should begin with a small amount (a half-gummy or less) and assess their individual response before consuming more [16].

Sources for this section: [9] Cannabinoid drug-interaction literature. [16] National Academies (2017). [20] Barrus et al., RTI Press 2016.

Regular use of THC-containing products can lead to the development of tolerance, meaning that more product may be required over time to achieve the same effect [16, 17]. Cannabis Use Disorder is a recognized clinical condition codified in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [25]. Cannabis Withdrawal is also a DSM-5-recognized syndrome and includes symptoms such as irritability or aggression, nervousness or anxiety, sleep difficulties, decreased appetite, restlessness, depressed mood, and physical symptoms (e.g., abdominal pain, tremor, sweating, headache) [25, 26]. Approximately 12% of frequent cannabis users in a nationally representative U.S. sample met DSM-5 cannabis withdrawal criteria in the past 12 months [26].

FDA has expressly stated that there are many important aspects about CBD that are not yet known, including [2]:

• What happens if CBD is taken daily for sustained periods of time.
• What level of intake triggers the known risks associated with CBD.
• How different methods of consumption (e.g., oral, topical, smoking, vaping) affect intake.
• The effect of CBD on the developing brain (such as on children who take CBD).
• The effects of CBD on the developing fetus or breastfed newborn.
• How CBD interacts with herbs and other plant materials.
• Whether CBD causes male reproductive toxicity in humans, as has been reported in studies of animals.

The bulleted list above is FDA's verbatim list of unresolved questions, taken from FDA's consumer update on CBD [2].

Sources for this section: [2] FDA Consumer Update on CBD. [16] National Academies (2017). [17] NIDA Research Report. [25] DSM-5-TR (APA 2022). [26] Livne/Hasin et al., Drug Alcohol Depend 2019; Connor et al., Addiction 2022.

This product contains Delta-9 THC and may cause a positive result on a drug test, including tests used by employers, athletic associations, courts, military services, and law-enforcement agencies [27]. Standard immunoassay screens detect THC and its primary urinary metabolite (THC-COOH); detection windows for chronic users can extend several weeks after last use [27, 28]. Even products labeled as containing only trace amounts of THC may produce a positive screen depending on the sensitivity of the test, the dose consumed, the frequency of use, and individual metabolism [28]. Use of this product may carry employment, legal, custody, immigration, or licensing consequences. Use at your own risk.

Sources for this section: [27] SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing Programs. [28] Huestis MA, Chem Biodivers 2007 ("Human Cannabinoid Pharmacokinetics").

NHTSA states that it is illegal to drive under the influence of drugs in all 50 states, Puerto Rico, and the District of Columbia, regardless of whether the substance is legal or illegal in the state of use [29]. Some states impose per se or zero-tolerance limits on THC or its metabolites; others rely on impairment-based statutes [29, 30]. Avoid the following activities until effects have fully worn off, which may take 8 hours or longer depending on dose and individual response [16, 20]: driving any motor vehicle, operating machinery or power tools, swimming, climbing or working at heights, using firearms, providing childcare, performing safety-sensitive job duties, or making significant legal or financial decisions.

Sources for this section: [16] National Academies (2017). [20] Barrus et al., RTI Press 2016. [29] NHTSA, "Drug-Impaired Driving." [30] GHSA, "Drug-Impaired Driving" state-law summary.

• Store between approximately 50–75°F (10–24°C). Keep out of direct sunlight and away from heat (consistent with manufacturer storage instructions printed on the package: "Keep in a cool, dry place. Avoid temperatures over 75°F. Keep out of direct sunlight").
• Keep in the original child-resistant pouch with the zipper sealed when not in use.
• Store in a location inaccessible to children, pets, and any visitors who have not consented to or are unaware of cannabis products [19, 23].
• Do not transfer the product into unmarked containers, candy jars, or any container that could be mistaken for a non-cannabis product [19].
• Do not consume after the expiration or best-by date printed on the package.
• Dispose of unused or expired product in a manner that prevents access by children, pets, or unintended consumers, in accordance with state and local law.

Sources for this section: Manufacturer's printed storage instructions on product package. [19] CDC HAN-00451. [23] Tweet et al., Pediatrics 2023.

If you experience an adverse event, side effect, or product quality issue with this product, you can report it through the channels below. Reporting helps FDA and manufacturers improve product safety. Reporting is voluntary.

FDA Reporting Channels

• Safety Reporting Portal: safetyreporting.hhs.gov [31].
• MedWatch: Call 1-800-FDA-1088 (1-800-332-1088) or visit fda.gov/safety/medwatch [32].
• CFSAN Adverse Event Reporting System (CAERS): For food-related adverse events, file via CAERS at fda.gov [33].

Manufacturer Contact

• K-Life Enterprises, Inc. dba Kanha: 1-866-988-7405 | kanhalife.com | 5062 Lankershim Blvd #137, North Hollywood, CA 91601 (per back panel of package).

Sources for this section: [31] HHS Safety Reporting Portal. [32] FDA MedWatch. [33] FDA CAERS

Poison Control & Other Resources

• U.S. Poison Control (Poison Help Line): 1-800-222-1222 — available 24/7, free, confidential, multilingual [34].
• ASPCA Animal Poison Control: 1-888-426-4435 (consultation fee may apply) [35].
• Pet Poison Helpline: 1-855-764-7661 (consultation fee may apply) [36].
• SAMHSA National Helpline (substance use): 1-800-662-HELP (4357) — free, confidential, 24/7 [37].
• 988 Suicide & Crisis Lifeline: Call or text 988 [38].

When contacting emergency services or poison control, share the product name, the cannabinoid content per gummy and per package (printed on packaging), the amount consumed, the time of consumption, and the age and weight of the person or pet who consumed it.

Sources for this section: [34] America's Poison Centers. [35] ASPCA Animal Poison Control. [36] Pet Poison Helpline. [37] SAMHSA National Helpline. [38] 988 Suicide & Crisis Lifeline.

This product is triple lab tested per the manufacturer's labeling on the package. Each batch is analyzed for cannabinoid potency and tested for contaminants in accordance with applicable state and industry standards. The Certificate of Analysis (COA) for the corresponding batch is available via the QR code on the package or through kanhalife.com. The lot number and batch information are printed on the package.

Sources for this section: Manufacturer's labeling printed on product package.

This product is intended to comply with the federal definition of hemp under the 2018 Agriculture Improvement Act, containing a total Delta-9 tetrahydrocannabinol concentration that does not exceed 0.3% on a dry-weight basis [1]. State laws regarding hemp-derived cannabinoid products vary and may change frequently. It is the consumer's responsibility to know and comply with the laws of the state in which they purchase, possess, transport, and consume this product. This product is not intended for shipment, sale, or use in any jurisdiction where its sale or possession is prohibited.

Sources for this section: [1] Agriculture Improvement Act of 2018 ("2018 Farm Bill"), Pub. L. No. 115-334.

These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This product is intended for use only by adults 21 years of age or older. Keep out of reach of children and pets. Do not use if pregnant or breastfeeding. Do not drive a motor vehicle or operate machinery while using this product. May cause drowsiness or impairment. Effects may be delayed up to 2 hours. May cause drug test failure. Use responsibly.

All citations below are to publicly available, primary sources: federal agency publications, peer-reviewed scientific literature, FDA-approved prescribing information, and established public-health and clinical reference materials. URLs are provided where the source is publicly accessible online; PubMed identifiers (PMID) and digital object identifiers (DOI) are provided for journal articles where available.

[1] Agriculture Improvement Act of 2018 ("2018 Farm Bill"), Pub. L. No. 115-334, 132 Stat. 4490; codified in part at 7 U.S.C. § 1639o (defining "hemp" as Cannabis sativa L. with not more than 0.3% Delta-9 THC by dry weight).

[2] U.S. Food and Drug Administration. "What You Need to Know (And What We're Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD." FDA Consumer Update. https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis

[3] U.S. Food and Drug Administration, Office of Food Additive Safety. "Scientific Memorandum: Cannabidiol (CBD)." January 19, 2022. https://www.fda.gov/media/169550/download

[4] Federal Food, Drug, and Cosmetic Act § 201(ff)(3)(B); 21 U.S.C. § 321(ff)(3)(B).

[5] EPIDIOLEX® (cannabidiol) oral solution. U.S. Prescribing Information. Jazz Pharmaceuticals, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210365s023lbl.pdf

[6] U.S. Food and Drug Administration, Center for Drug Evaluation and Research. "CDER Investigators Address the Safety of CBD in a Randomized Trial." August 25, 2025. https://www.fda.gov/drugs/regulatory-science-action/cder-investigators-address-safety-cbd-randomized-trial

[7] Florian J, Salcedo P, Burkhart K, Shah A, Chekka LMS, Keshishi D, Patel V, Yang S, Fein M, DePalma R, Matta M, Strauss DG, Rouse R. "Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial." JAMA Internal Medicine. 2025;185(9). DOI: 10.1001/jamainternmed.2025.2366. PMID: 40622698.

[8] U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. https://www.ncbi.nlm.nih.gov/books/NBK547852/

[9] Brown JD, Winterstein AG. "Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use." Journal of Clinical Medicine. 2019;8(7):989. DOI: 10.3390/jcm8070989. See also: Doohan PT, Oldfield LD, Arnold JC, Anderson LL. "Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: A Full-Spectrum Characterization." The AAPS Journal. 2021;23(4):91. DOI: 10.1208/s12248-021-00616-7.

[10] Smythe MA, Wu W, Garwood CL, et al. "Anticoagulant drug-drug interactions with cannabinoids: A systematic review." Pharmacotherapy. 2023;43(11):1158-1175. DOI: 10.1002/phar.2881.

[11] Grayson L, Vines B, Nichol K, Szaflarski JP. "An interaction between warfarin and cannabidiol, a case report." Epilepsy & Behavior Case Reports. 2018;9:10-11. DOI: 10.1016/j.ebcr.2017.10.001. PMID: 29387536.

[12] International Association of Chiefs of Police, Drug Recognition Expert Section. "The 7 Drug Categories." https://www.theiacp.org/7-drug-categories

[13] Carvalho RK, Andersen ML, Mazaro-Costa R. "The effects of cannabidiol on male reproductive system: A literature review." Journal of Applied Toxicology. 2020;40(1):132-150. DOI: 10.1002/jat.3831. PMID: 31313338.

[14] U.S. Food and Drug Administration. "What You Should Know About Using Cannabis, Including CBD, When Pregnant or Breastfeeding." FDA Consumer Update. https://www.fda.gov/consumers/consumer-updates/what-you-should-know-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding

[15] U.S. Surgeon General. "U.S. Surgeon General's Advisory: Marijuana Use and the Developing Brain." 2019. https://www.hhs.gov/surgeongeneral/reports-and-publications/addiction-and-substance-misuse/advisory-on-marijuana-use-and-developing-brain/index.html

[16] National Academies of Sciences, Engineering, and Medicine. "The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research." Washington, DC: The National Academies Press; 2017. DOI: 10.17226/24625.

[17] National Institute on Drug Abuse (NIDA), National Institutes of Health. "Cannabis (Marijuana) Research Report." https://nida.nih.gov/publications/research-reports/marijuana

[18] U.S. Food and Drug Administration. "5 Things to Know About Delta-8 Tetrahydrocannabinol – Delta-8 THC." FDA Consumer Update. https://www.fda.gov/consumers/consumer-updates/5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc

[19] Centers for Disease Control and Prevention, Health Alert Network. "Increases in Availability of Cannabis Products Containing Delta-8 THC and Reported Cases of Adverse Events." CDCHAN-00451. September 14, 2021. https://archive.cdc.gov/emergency_cdc_gov/han/2021/han00451.asp

[20] Barrus DG, Capogrossi KL, Cates SC, Gourdet CK, Peiper NC, Novak SP, Lefever TW, Wiley JL. "Tasty THC: Promises and Challenges of Cannabis Edibles." RTI Press Methods Report Series; 2016. DOI: 10.3768/rtipress.2016.op.0035.1611. PMID: 28127591.

[21] Allen JH, de Moore GM, Heddle R, Twartz JC. "Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse." Gut. 2004;53(11):1566-1570. DOI: 10.1136/gut.2003.036350. PMID: 15479672. See also: Cleveland Clinic, "Cannabinoid Hyperemesis Syndrome (CHS)." https://my.clevelandclinic.org/health/diseases/21665-cannabis-hyperemesis-syndrome

[22] Manseau MW, Goff DC. "Cannabinoids and Schizophrenia: Risks and Therapeutic Potential." Neurotherapeutics. 2015;12(4):816-824. DOI: 10.1007/s13311-015-0382-6. PMID: 26311150.

[23] Tweet MS, Nemanich A, Wahl M. "Pediatric Edible Cannabis Exposures and Acute Toxicity: 2017–2021." Pediatrics. 2023;151(2):e2022057761. DOI: 10.1542/peds.2022-057761. PMID: 36594224.

[24] Cornell University College of Veterinary Medicine, Riney Canine Health Center. "Cannabis (THC) intoxication in dogs." https://www.vet.cornell.edu/departments-centers-and-institutes/riney-canine-health-center/canine-health-information/Cannabis-THC-intoxication-in-dogs

[25] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022. (Cannabis Use Disorder; Cannabis Withdrawal.)

[26] Livne O, Shmulewitz D, Lev-Ran S, Hasin DS. "DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults." Drug and Alcohol Dependence. 2019;195:170-177. DOI: 10.1016/j.drugalcdep.2018.09.005. PMID: 30551036. See also: Connor JP, Stjepanović D, Le Foll B, et al. "Clinical management of cannabis withdrawal." Addiction. 2022;117(7):2075-2095. DOI: 10.1111/add.15743.

[27] Substance Abuse and Mental Health Services Administration (SAMHSA). "Mandatory Guidelines for Federal Workplace Drug Testing Programs." https://www.samhsa.gov/workplace/resources/mandatory-guidelines

[28] Huestis MA. "Human Cannabinoid Pharmacokinetics." Chemistry & Biodiversity. 2007;4(8):1770-1804. DOI: 10.1002/cbdv.200790152. PMID: 17712819.

[29] U.S. National Highway Traffic Safety Administration (NHTSA). "Drug-Impaired Driving." https://www.nhtsa.gov/risky-driving/drug-impaired-driving and "Countermeasures That Work — Drug-Impaired Driving." https://www.nhtsa.gov/book/countermeasures-that-work/drug-impaired-driving

[30] Governors Highway Safety Association. "Drug-Impaired Driving" — state-by-state legal summary. https://www.ghsa.org/state-laws-issues/drug-impaired-driving

[31] U.S. Department of Health and Human Services. "Safety Reporting Portal." https://www.safetyreporting.hhs.gov

[32] U.S. Food and Drug Administration. "MedWatch: The FDA Safety Information and Adverse Event Reporting Program." https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

[33] U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition. "CFSAN Adverse Event Reporting System (CAERS)." https://www.fda.gov/food/compliance-enforcement-food/cfsan-adverse-event-reporting-system-caers

[34] America's Poison Centers (formerly American Association of Poison Control Centers). Poison Help Line: 1-800-222-1222. https://poisonhelp.hrsa.gov/

[35] American Society for the Prevention of Cruelty to Animals (ASPCA), Animal Poison Control Center. https://www.aspca.org/pet-care/animal-poison-control

[36] Pet Poison Helpline. https://www.petpoisonhelpline.com/

[37] Substance Abuse and Mental Health Services Administration (SAMHSA), National Helpline. https://www.samhsa.gov/find-help/national-helpline

[38] 988 Suicide & Crisis Lifeline. https://988lifeline.org/